Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) announced that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. and Chief Financial Officer Andrew Saik will present in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The presentation is scheduled for Thursday, December 4, 2025 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s Events and Presentations web page.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ARVN gained 2.48%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer moves were mixed: OLMA up 4.52%, XNCR up 0.41%, while SAGE, NRIX, and VSTM declined between 0.69% and 5.7%. With no peers in the momentum scanner and no same-day peer headlines, ARVN’s setup ahead of this conference appearance looks more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Investor conference | Neutral | +2.5% | Management scheduled a Piper Sandler fireside chat with webcast access. |
| Nov 24 | Clinical data preview | Positive | +2.2% | Multiple vepdegestrant abstracts accepted for presentation at SABCS 2025. |
| Nov 05 | Earnings and pipeline | Positive | +0.3% | Q3 2025 results with pipeline progress and NDA acceptance for vepdegestrant. |
| Nov 03 | Preclinical conference | Positive | -1.9% | Preclinical ARV-393 data to be presented at the ASH 2025 meeting. |
| Nov 03 | Investor conferences | Neutral | -4.1% | Participation in Guggenheim and Jefferies healthcare investor conferences. |
Recent ARVN news has often seen modest positive reactions to clinical and earnings updates, while some conference-related announcements have coincided with negative or muted moves, indicating selective investor focus on data-rich catalysts.
Over the last few months, Arvinas highlighted several milestones. A Q3 2025 update on Nov 5 detailed financials, pipeline progress, and an NDA acceptance for vepdegestrant with a June 5, 2026 PDUFA date. Multiple conference and clinical-data announcements followed in November, including SABCS abstracts and ASH preclinical data. Today’s Piper Sandler appearance continues a pattern of active investor and scientific engagement rather than introducing new clinical or financial data.
Market Pulse Summary
This announcement outlines Arvinas management’s participation in a Piper Sandler healthcare conference, adding to a series of investor and scientific engagements in late 2025. It does not introduce new clinical or financial information. In context of recent trial updates, an NDA acceptance with a June 5, 2026 PDUFA date, and significant cash resources, investors may watch whether discussion at the fireside chat reiterates or extends these existing themes.
AI-generated analysis. Not financial advice.
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4 at 11:00 a.m. ET in New York.
A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When will Arvinas (ARVN) present at the Piper Sandler 37th Annual Healthcare Conference?
Who from Arvinas will speak at the Piper Sandler conference for ARVN?
How can investors listen to the Arvinas (ARVN) presentation on December 4, 2025?
Where is the Piper Sandler 37th Annual Healthcare Conference taking place for Arvinas' presentation?
Will Arvinas (ARVN) make the presentation recording available after the conference?
What topics are Arvinas executives likely to cover in the ARVN fireside chat on December 4, 2025?
